# BPC-157 TB-500 References: The Cited Studies and FDA Sources

> BPC-157 TB-500 references — every study, review, and FDA source cited across this Wolverine-blend digest, with DOIs, PubMed links, and the FDA 503A pages.

Peer-reviewed studies and reviews for each constituent, plus the FDA pages behind the 503A access status. DOIs and PubMed links throughout.

## How to read this list

Every citation marked `[N]` across this site resolves to a numbered entry below. The studies on each constituent of the BPC-157 TB-500 blend are peer-reviewed primary research or reviews; the regulatory entries are FDA pages verified to load and contain the cited content, plus the WADA Prohibited List for anti-doping status.

References 1-12 are the scientific record on the two peptides. References 13-16 are the access and anti-doping sources behind the [Wolverine legal status and FDA 503A category](/legal-status). Where a study used animal models, the citation reflects that — none of these entries should be read as human-use evidence for the combination.

## References

[1] Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[2] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[3] Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. https://pubmed.ncbi.nlm.nih.gov/15329672/
[4] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. https://pubmed.ncbi.nlm.nih.gov/22074294/
[5] Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. https://pubmed.ncbi.nlm.nih.gov/22962027/
[6] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/
[7] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[8] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/
[9] Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. Pharmaceutics. 2025;17(1):119. https://pubmed.ncbi.nlm.nih.gov/39861766/
[10] Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury. Medicina (Kaunas). 2025;61(2):291. https://pubmed.ncbi.nlm.nih.gov/40005408/
[11] Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. https://pubmed.ncbi.nlm.nih.gov/40005999/
[12] The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024;17(4):461. https://pubmed.ncbi.nlm.nih.gov/38675421/
[13] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2 entries for BPC-157 and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; list update effective September 29, 2023). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
[14] U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (BPC-157 and TB-500 listed as bulk drug substances being considered for inclusion on the 503A Bulks List). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
[15] U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 1 / Category 2 framework and the 503A/503B compounding pathway). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
[16] World Anti-Doping Agency. The Prohibited List (BPC-157 under category S0 Non-Approved Substances; TB-500 / thymosin beta-4 under prohibited peptide and tissue-repair categories). https://www.wada-ama.org/en/prohibited-list

---

A street-wall research digest on the BPC-157 TB-500 Wolverine blend — each peptide tagged to its own studies, every blend-level gap sprayed in plain sight beside the FDA 503A line, with no clinic behind the wall and nothing here to dispense.